Drug intelligence / Profile preview

MAX001

Development stage: Preclinical
Lead developer: Maxion Therapeutics
Administration: Oral

Overview

MAX001 is a lead preclinical program developed by Maxion Therapeutics, a UK-based biotech company. It is based on the company's proprietary KnotBody® platform, which is designed for drugging ion channels and G protein-coupled receptors (GPCRs). The drug is being advanced for the treatment of autoimmune inflammatory diseases, specifically mentioning atopic dermatitis and inflammatory bowel disease, with further programs targeting pain and cardiovascular disease. Maxion Therapeutics raised $72 million in Series A financing to move MAX001 to clinical proof-of-concept.

Beyond the preview

Go deeper on MAX001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX001.

Explore the full profile